MACI (matrix-induced autologous chondrocyte implant) / Vericel - LARVOL DELTA

MASCOT: A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle (clinicaltrials.gov) - P3 | N=309 | Recruiting | Sponsor: Vericel Corporation | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date

MASCOT: A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle (clinicaltrials.gov) - P3 | N=309 | Recruiting | Sponsor: Vericel Corporation | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2030 ➔ Jul 2030 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Apr 2030 ➔ Jul 2030

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

MASCOT: A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle (clinicaltrials.gov) - P3 | N=276 | Not yet recruiting | Sponsor: Vericel Corporation

New P3 trial

PEAK: A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (clinicaltrials.gov) - P3 | N=45 | Recruiting | Sponsor: Vericel Corporation | Trial completion date: Jun 2025 ➔ Jun 2027 | Trial primary completion date: Jun 2025 ➔ Jun 2027

Trial completion date • Trial primary completion date

"$VCEL Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee https://t.co/6soPUPh6Q0" (@otcdynamics)

Use of MACI (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) in the United States: Preliminary Experience. (PubMed, Orthop J Sports Med) - "Data were collected for 1000 consecutive patients starting on July 1, 2017, when Carticel (the prior generation of autologous cultured chondrocytes) was no longer available. Patient age and mean total MACI-treated defect size in the United States are similar to the findings of the pivotal European SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) trial and other studies from outside the United States. Treatment of multiple cartilage defects is more frequent in the United States than elsewhere."

Journal • Preclinical • Musculoskeletal Diseases

"$VCEL Dan Orlando discusses MACI product innovation with ABC7 @BloomTV #JPM18 highlights of hot technologies for 2018 @russopartners @VericelCorp @SolomonsWisdom" (@davidschull)

Biosimilar

Demographics in Patients Receiving Matrix-Assisted Chondrocyte Implantation (MACI) in the Ankle. (PubMed, Cartilage) - "The sizes of treated defects followed the general recommendations. There were, however, significant differences between countries."

Clinical • Journal

"Representing @VericelCorp talking about #cartilage #MACI #jointpreservation for the #2019orthopaedicupdate meeting . Aloha!" (@doccasslee)

"Team #MACI at #SBLIII Radio Row https://t.co/hKCp44ilve @VericelCorp @russopartners @SolomonsWisdom" (@davidschull)

"We will see you on @atlsuperbowl53 #RadioRow with @VericelCorp Jan. 29-30 #SBLIII #ATL #MACI @russopartners" (@davidschull)